FDA Just Posted a $12 Million Complex Generics RFA. Exactly One University Can Apply.
November 18, 2026 · 7 min read
Granted Research Team · Editorial policy
Academic PIs who track NIH receipt dates should look at a non-NIH one: FDA posted RFA-FD-27-001, Research on Complex Generics, to Grants.gov on November 13, 2026 with a December 14 due date and a $2.5 million annual ceiling — and exactly one eligible applicant.
That last clause is the story. Most coverage of a newly posted federal research announcement starts with the science. This one has to start with Section III, because Section III makes the other fourteen pages conditional.
The eligibility section is one sentence long
The full announcement on Grants.gov runs fifteen pages and reads like an NIH NOFO: SF424(R&R) forms, eRA Commons IDs, a Data Management and Sharing Plan, a Vertebrate Animals review criterion. Then Section III, Eligible Organizations, says this in full:
Only the following applicant is eligible to apply for this single source funding: The University of Maryland
There is no second sentence. The Application Types Allowed field says Renewal — not New, not Resubmission. Non-domestic entities are excluded, and so are foreign components of U.S. organizations, as defined in the NIH Grants Policy Statement.
Put those two fields together and RFA-FD-27-001 is not a competition. It is the administrative vehicle for continuing an award that already exists, run through the public Grants.gov pipeline because federal financial assistance has to be announced publicly even when the field is one.
The mechanics are worth having straight, because the numbers are real money regardless of who can touch them. The activity code is U18, a cooperative agreement — an assistance mechanism "in which substantial FDA programmatic involvement with the recipients is anticipated." The Assistance Listing is 93.103, Food and Drug Administration Research. The participating component is the Center for Drug Evaluation and Research, and the scientific contact is Sam Raney, PhD, in CDER's Office of Generic Drugs. Applications are due by 11:59 p.m. local time of the applicant organization on December 14, 2026; the announcement expires December 15 and archives January 13, 2027. There is no cost sharing, and the NOFO states flatly that no late applications will be accepted.
What $12 million buys, and on what ladder
FDA intends to fund up to $2,000,000 in fiscal year 2027 under this program, with one award anticipated, "not to exceed $2,500,000 in total costs (direct plus indirect) per year." The budget ladder in Section II is explicit:
| Year | Total costs (direct + indirect) |
|---|---|
| YR 01 | $2,000,000 |
| YR 02 | $2,500,000 |
| YR 03 | $2,500,000 |
| YR 04 | $2,500,000 |
| YR 05 | $2,500,000 |
Maximum project period is five years, earliest start date January 1, 2027. The full ladder totals $12 million, with years two through five contingent on annual appropriations, availability of funding, and satisfactory performance — the standard HHS out-year language, and the standard HHS caveat.
Two things are notable about that table for anyone who writes multi-year federal budgets. First, year one is the trough, not the peak: FDA is funding $2.0 million against a $2.5 million ceiling, so the recipient absorbs a half-million-dollar ramp in year two. Second, the ceiling is stated in total costs. Indirect sits inside the cap, not on top of it, which at a research university's negotiated rate means the direct-cost program is materially smaller than $2.5 million. That distinction has been the subject of a much larger fight this year, which we covered in the FY2026 research budget and indirect cost rate battle — and it applies here in miniature.
The 2020 version of this RFA was a genuinely open competition
The useful comparison is the predecessor. In January 2020, FDA posted RFA-FD-20-007, "Center for Collaborative Research on Complex Generics (U18) Clinical Trials Optional." Same activity code, same assistance listing, same office. One award anticipated, with an award floor of $1,000,000 and a ceiling of $5,000,000.
The eligibility section of that announcement was the opposite of this one. It listed public and private institutions of higher education, HBCUs, Tribally Controlled Colleges and Universities, Hispanic-serving institutions, nonprofits with and without 501(c)(3) status, small businesses, for-profit organizations, state and local governments, tribal governments, faith-based and community organizations — and non-domestic entities. Posted January 7, 2020, closing May 13, 2020: a 127-day window.
RFA-FD-27-001 gives its single eligible applicant 31 days.
That 2020 competition produced the Center for Research on Complex Generics. Per the center's own About page, "In 2020, the University of Maryland School of Pharmacy and the University of Michigan College of Pharmacy received a U.S. Food and Drug Administration (FDA) U18 grant to form the Center for Research on Complex Generics (CRCG)." The 2026 announcement is the renewal of that award, and the "University of Maryland" in Section III is the prime; Michigan has been the partner institution since the center's founding.
So the honest read for an academic PI is this: the open competition for this money happened six years ago, and the next one will not happen until 2031 at the earliest — if the renewal runs its full five years.
The review is FDA's, not NIH's, and one criterion is about industry
RFA-FD-27-001 is still worth reading closely, because FDA's RFA-FD- series is procedurally different from NIH in ways that catch investigators who assume the two are interchangeable. Page one of the NOFO says so directly:
The FDA does not follow the NIH Page Limitation Guidelines or the NIH Review Criteria.
Applications here are "evaluated for scientific and technical merit by an FDA programmatic review team" — not a chartered study section. There are five criteria, each scored separately at a maximum of 20 points: Significance, Investigator(s), Innovation, Approach, and Environment. A flat 100-point scale, not the NIH 1–9 overall impact score.
The Environment criterion is where FDA's priorities show. Alongside the usual questions about institutional support and physical resources, it asks:
Does the applicant demonstrate relationships with scientific investigators who have suitable expertise and understand the goals of the generic drug research program? Does the applicant demonstrate the ability to engage effectively with the generic drug industry?
That is not an NIH question. FDA is scoring convening capacity — whether the recipient can pull generic manufacturers, academic labs, and regulators into the same room. The Program Characteristics section makes the same point from the other direction: applicants may request funding for "scientific and educational workshops... for horizon scanning of emerging fields or trends in generic drug research," alongside research in analytical methods, modeling and simulation, formulation science, and clinical and pre-clinical development.
The cooperative agreement terms spell out what FDA does with its substantial involvement: "Provide federal public health, generic drug research priorities annually" and "Provide subject matter expertise in the areas of research translation, study and workshop design." Annual priority-setting by the sponsor is the defining feature of this award. The science is steered year by year from inside CDER.
The scientific problem itself is stated in the Background section, and it is a real one. Barriers to generic market entry persist for products "with complex active ingredients, formulations, routes of delivery, dosage forms, or drug-device combination components." The GDUFA science and research program exists to fund "more efficient bioequivalence methodologies, analytical tools, and regulatory frameworks" for exactly those products. When the barriers hold, per the NOFO, "patients face higher drug costs, supply vulnerabilities, and reduced access to essential therapies."
One procedural note that applies well beyond this announcement: Section IV carries HHS's current funding-restriction language on discretionary awards, requiring that all proposed activities and budget narratives align with applicable statutes, executive orders, federal regulations, and judicial holdings, and stating that non-aligned applications will not receive funding to the extent permitted by law. That clause is now standard across FDA NOFOs, and budget narratives are explicitly in scope.
Where this money actually reaches outside investigators
If you cannot be the applicant, the question becomes whether you can be downstream of it. For complex generics, the answer is yes, and the channel is the center rather than Grants.gov.
CRCG runs its own calls — for data contributions, materials contributions, subject-matter experts, and discrete research topics such as in vitro approaches to comparing adhesion performance of transdermal and topical delivery systems. Its stated mission includes "conducting collaborative research and enabling pilot research projects and technological development," and its collaboration page is an open intake form rather than an eligibility screen. The center also runs workshops; a long-acting injectable generics workshop is listed on its calendar for December 1–2, 2026.
Three moves follow from that, and the December 14 date is not the one that matters for most readers:
- Get on the center's distribution list now. Its calls are not posted to Grants.gov and do not carry FON numbers. If you only watch federal announcement feeds, you will not see them.
- Watch for the FY2027 priorities, not the award notice. FDA commits to publishing generic drug research priorities annually under this agreement. Those priorities are the leading indicator for what the center will solicit twelve to eighteen months out.
- Position on the Environment criterion. FDA is paying for industry engagement capacity. A lab with documented generic-manufacturer relationships is a more valuable subaward partner here than one with a stronger publication record and no industry contacts.
The broader lesson generalizes past complex generics. Single-source renewals look like open opportunities in every search index that reads the title and the dollar figure and stops there. Reading Section III first — before the science, before the budget — is the fastest filter in federal grant-seeking, and it takes about ten seconds.
For the receipt dates that are open to competing academic applicants right now, the WTC Health Program's paired U01 and R21 announcements close the same month; we broke down RFA-OH-26-001 and RFA-OH-26-015 and their December 8 deadline earlier this fall.
Next step: Search active bioequivalence and generic drug development solicitations on Granted to find the open-competition analogues to this award — and set an alert on Assistance Listing 93.103 so the next FDA research RFA that is competed reaches you on posting day, not 31 days before it closes.